Clinical Trials

193 results for Bladder Cancer


Molecular Correlates of Sensitivity and Resistance to Therapy in Genitourinary Malignancy

  • Condition: Healthy Control, Localized Urothelial Carcinoma of the Renal Pelvis and Ureter, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Soft Tissues, Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter, Recurrent Bl
  • Intervention: Other: Cytology Specimen Collection Procedure, Other: Laboratory Biomarker Analysis
  • Study ID: NCT01050504
View Trial

PET/MRI and Biomarkers in Clinical Staging of Bladder Cancer and in the Estimation of Neoadjuvant Chemotherapy Response Prior to Radical Cystectomy

  • Condition: Bladder Cancer
  • Intervention: Device: MRI/acetate-PET imaging
  • Study ID: NCT01918592
View Trial

Familial and Atypical Urothelial Cancer Registry

  • Condition: Urothelial Cancer, Renal Pelvis Cancer, Ureter Cancer, Bladder Cancer
  • Intervention: Other: saliva sample and questionaire, Other: saliva sample, questionaire
  • Study ID: NCT00902590
View Trial

Biomarker Identification for Bladder Cancer Patients

  • Condition: Bladder Cancer
  • Intervention: Procedure: Sample Collection
  • Study ID: NCT02053662
View Trial

Phase I Dose-Escalation Study of Image-Guided Radiation Therapy for Bladder-Cancer Patients Undergoing Radiotherapy and Concurrent Gemcitabine Chemotherapy

  • Condition: Bladder Cancer
  • Intervention: Other: external radiation therapy with gemcitabine
  • Study ID: NCT01104350
View Trial

Identifying Genetic Predictors of Durable Clinical Benefit to Pembrolizumab in Advanced or Recurrent Cancers

  • Condition: Carcinoma, Non-Small-Cell Lung, Cancer of the Head and Neck, Urinary Bladder Neoplasms, Esophageal Squamous Cell Carcinoma, Carcinoma, Transitional Cell
  • Intervention: Drug: Pembrolizumab
  • Study ID: NCT02710396
View Trial

LCCC 1209: Pilot Study of [18F] Fluorodeoxyglucose Positron Emission Tomography-Magnetic Resonance Imaging (FDG-PET-MRI) for Staging of Muscle-Invasive Bladder Cancer

  • Condition: Bladder Cancer
  • Intervention: Procedure: FDG PET/MR
  • Study ID: NCT01655745
View Trial

Adjuvant Radiotherapy After Cystectomy for Patients With Muscle Invasive Bladder Cancer: a Phase II Trial.

  • Condition: Toxicity
  • Intervention: Radiation: Adjuvant EBRT
  • Study ID: NCT02397434
View Trial

A Randomized Phase II Trial Evaluating an Organ-conserving Strategy With Radiotherapy + CDDP + Gemcitabine vs Radiotherapy + CDDP in Muscle-infiltrative Bladder Cancer

  • Condition: Infiltrating Bladder Urothelial Carcinoma
  • Intervention: Other: Radiation + cisplatin, Other: Radiation + cisplatin + gemcitabine
  • Study ID: NCT01495676
View Trial

A Phase III Surgical Trial to Evaluate the Benefit of a Standard Versus an Extended Pelvic Lymphadenectomy Performed at Time of Radical Cystectomy for Muscle Invasive Urothelial Cancer

  • Condition: Bladder Cancer
  • Intervention: Procedure: therapeutic conventional surgery, Procedure: therapeutic lymphadenectomy
  • Study ID: NCT01224665
View Trial

A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of Avelumab (MSB0010718C) in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Select

  • Condition: Solid Tumors
  • Intervention: Drug: Avelumab
  • Study ID: NCT01772004
View Trial

A Phase I/1b Study of Enzalutamide in Combination With Gemcitabine and Cisplatin in Bladder Cancer

  • Condition: Bladder Cancer, Carcinoma, Transitional Cell, Renal Pelvis Cancer, Ureter Cancer, Urethra Cancer
  • Intervention: Drug: Enzalutamide, Drug: Cisplatin, Drug: Gemcitabine
  • Study ID: NCT02300610
View Trial

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Ramucirumab Plus Docetaxel Versus Placebo Plus Docetaxel in Patients With Locally Advanced or Unresectable or Metastatic Urothelial Carcinoma Who Progressed on or After Platinum-Based Therap

  • Condition: Urothelial Carcinoma
  • Intervention: Drug: Ramucirumab, Drug: Docetaxel, Drug: Placebo
  • Study ID: NCT02426125
View Trial

Prophylactic Cranial Irradiation (PCI) for Patients With Small Cell Carcinoma of the Urothelium

  • Condition: Bladder Cancer
  • Intervention: Radiation: Prophylactic Cranial Irradiation (PCI), Other: Brain X-ray
  • Study ID: NCT00756639
View Trial

A Prospective Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery for Patients With High Grade Upper Tract Urothelial Carcinoma

  • Condition: Localized Urothelial Carcinoma of the Renal Pelvis and Ureter, Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter, Regional Urothelial Carcinoma of the Renal Pelvis and Ureter
  • Intervention: Drug: Methotrexate, Drug: Vinblastine, Drug: Doxorubicin Hydrochloride, Drug: Cisplatin, Drug: Gemcitabine Hydrochloride, Drug: Carboplatin, Procedure: Therapeutic Conventional Surgery, Other: Laboratory Biomarker Analysis
  • Study ID: NCT02412670
View Trial

Phase II Trial of Gemcitabine-Eribulin (GE) in Cisplatin Ineligible Patients With Advanced or Unresectable Urothelial Carcinoma of the Bladder

  • Condition: Metastatic Ureteral Neoplasm, Metastatic Urethral Neoplasm, Stage III Bladder Urothelial Carcinoma, Stage III Ureter Cancer, Stage III Urethral Cancer, Stage IV Bladder Urothelial Carcinoma, Stage IV Ureter Cancer, Stage IV Urethral Cancer, Ureter
  • Intervention: Drug: Eribulin Mesylate, Drug: Gemcitabine Hydrochloride
  • Study ID: NCT02178241
View Trial

Pembrolizumab With Chemoradiotherapy as Treatment for Muscle Invasive Bladder Cancer

  • Condition: Bladder Cancer
  • Intervention: Drug: Pembrolizumab, Drug: Cisplatin, Radiation: Radiotherapy
  • Study ID: NCT02662062
View Trial

A Phase III, Open-Label, Multicenter, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) Versus Observation as Adjuvant Therapy in Patients With PD-L1-Selected, High-Risk Muscle-Invasive Bladder Cancer After Cystectomy

  • Condition: Bladder Cancer, Cancer
  • Intervention: Drug: Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody
  • Study ID: NCT02450331
View Trial

A Phase III, Open Label Study to Evaluate the Safety and Efficacy of INSTILADRIN® (rAd-Interferon (IFN)/Syn3) Administered Intravesically to Patients With High Grade, BCG Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC)

  • Condition: Superficial Bladder Cancer
  • Intervention: Biological: INSTILADRIN
  • Study ID: NCT02773849
View Trial

The Value of Immediate Post-operative Intravesical Epirubicin Instillation in Intermediate and High Risk Non Muscle Invasive Bladder Cancer (NMIBC): A Randomized Controlled Trial

  • Condition: Carcinoma of Urinary Bladder, Superficial
  • Intervention: Drug: Epirubicin
  • Study ID: NCT02214602
View Trial

A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line MEDI4736 Monotherapy and MEDI4736 in Combination With Tremelimumab Versus Standard of Care Chemotherapy in Patients With Unresectable Stage IV Urothelial Cancer

  • Condition: Urothelial Cancer
  • Intervention: Drug: MEDI4736, Drug: Tremelimumab, Drug: Cisplatin, Drug: Carboplatin, Drug: Gemcitabine
  • Study ID: NCT02516241
View Trial

A Phase III, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of Atezolizumab (Anti PD-L1 Antibody) in Combination With Gemcitabine/Carboplatin Versus Gemcitabine/Carboplatin Alone in Patients With Untreated Locally Advanced or Metastatic U

  • Condition: Bladder Cancer, Urothelial Carcinoma
  • Intervention: Drug: Atezolizumab, Drug: Carboplatin, Drug: Gemcitabine, Other: Placebo
  • Study ID: NCT02807636
View Trial

A Phase III Randomized, Controlled Clinical Trial of Pembrolizumab With or Without Platinum-Based Combination Chemotherapy Versus Chemotherapy in Subjects With Advanced or Metastatic Urothelial Carcinoma

  • Condition: Urothelial Carcinoma Associated 1 RNA, Human
  • Intervention: Biological: Pembrolizumab, Drug: Cisplatin, Drug: Carboplatin, Drug: Gemcitabine
  • Study ID: NCT02853305
View Trial

A Phase 3, Open-label, Randomized Study of Nivolumab Combined With Ipilimumab Versus Standard of Care Chemotherapy in Participants With Previously Untreated Unresectable or Metastatic Urothelial Cancer

  • Condition: Urothelial Cancer
  • Intervention: Biological: nivolumab, Biological: ipilimumab, Drug: Gemcitabine, Drug: cisplatin, Drug: carboplatin
  • Study ID: NCT03036098
View Trial

A Phase 3 Randomized, Double-blind, Multi-center Study of Adjuvant Nivolumab Versus Placebo in Subjects With High Risk Invasive Urothelial Carcinoma (CheckMate 274: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 274)

  • Condition: Various Advanced Cancer
  • Intervention: Biological: Nivolumab, Other: Placebo
  • Study ID: NCT02632409
View Trial

A Phase 3, Multicenter, Multinational, Randomized, Open-label, Parallel-arm Study Of Avelumab* (msb0010718c) Plus Best Supportive Care Versus Best Supportive Care Alone As A Maintenance Treatment In Patients With Locally Advanced Or Metastatic Urothelial

  • Condition: Urothelial Cancer
  • Intervention: Biological: Avelumab, Other: Best Supportive Care
  • Study ID: NCT02603432
View Trial

A Phase 1 Study of the Safety and Pharmacokinetics of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4

  • Condition: Metastatic Urothelial Cancer and Other Malignant Solid Tumors
  • Intervention: Drug: ASG-22CE
  • Study ID: NCT02091999
View Trial

An Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Multi-Centre, Multi-arm Phase 1b Study in Patients With Muscle Invasive Bladder Cancer (MIBC) Who Have Progressed on Prior Treatment (BISCAY)

  • Condition: Muscle Invasive Bladder Cancer
  • Intervention: Drug: AZD4547, Drug: Durvalumab + AZD4547, Drug: Durvalumab + Olaparib, Drug: Durvalumab + AZD1775, Drug: Durvalumab monotherapy
  • Study ID: NCT02546661
View Trial

Improving Clinical Staging for Muscle Invasive Bladder Cancer Through Molecular Profiling and Improved Imaging

  • Condition: Bladder Cancer
  • Intervention: Procedure: Tissue Biopsy, Procedure: Magnetic Resonance Imaging (MRI)
  • Study ID: NCT02203136
View Trial

Muscle Invasive Bladder Cancer: External Beam Radiotherapy as an Alternative for Cystectomy

  • Condition: Toxicity
  • Intervention: Radiation: external beam radiotherapy (EBRT)
  • Study ID: NCT02748200
View Trial

A Phase 1b, Multicenter, Open Label Study Evaluating Safety, Tolerability and Preliminary Efficacy of GemRIS 225 mg in Subjects With Muscle-Invasive Transitional Cell Carcinoma of the Bladder

  • Condition: Urinary Bladder Cancer
  • Intervention: Drug: Gemcitabine-Releasing Intravesical System (GemRIS)
  • Study ID: NCT02722538
View Trial

Impact of Positron Emission Tomography (PET) Imaging in Muscle-invasive Urothelial Carcinoma of the Bladder Staging

  • Condition: Muscle-invasive Bladder Cancer
  • Intervention: Other: Whole-body FDG PET-CT
  • Study ID: NCT02462239
View Trial

Phase II Single Arm Study of Gemcitabine and Cisplatin Plus Pembrolizumab as Neoadjuvant Therapy Prior to Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer

  • Condition: Bladder Cancer
  • Intervention: Drug: pembrolizumab, gemcitabine and cisplatin
  • Study ID: NCT02690558
View Trial

Identification and Treatments of Basal Like Bladder Cancer (Study on Human Tumor Samples and Animal Models)

  • Condition: Muscle Invasive Bladder Cancer, Molecular Taxonomy
  • Intervention: Other: biomarker study
  • Study ID: NCT02648100
View Trial

A Randomized Phase II Study of Co-Expression Extrapolation (COXEN) With Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer

  • Condition: Bladder Cancer
  • Intervention: Drug: Gemcitabine, Drug: Cisplatin, Drug: Methotrexate, Drug: Vinblastine, Drug: Doxorubicin, Drug: Filgrastim
  • Study ID: NCT02177695
View Trial

Prospective Cohort Study of Transurethral Resection of Bladder Tumor (TURBT) Combined With Adjuvant Intravenous GC Chemotherapy to Prevent Moderate-high Recurrence and Progression Risks of Muscle-invasive Bladder Cancer

  • Condition: Bladder Cancer, Gemcitabine and Cisplatin Chemotherapy, Epirubicin Instillation, Recurrence, Prognosis
  • Intervention: Drug: Gemcitabine, cisplatin
  • Study ID: NCT02716961
View Trial

Phase Ib/II Study of Neoadjuvant Pembrolizumab With Gemcitabine-Cisplatin (Cisplatin-Eligible) or Gemcitabine (Cisplatin-Ineligible) in Subjects With T2-4aN0M0 Urothelial Cancer: HCRN GU14-188

  • Condition: Urothelial Carcinoma, Bladder Cancer
  • Intervention: Drug: Pembrolizumab, Drug: Gemcitabine, Drug: Cisplatin, Procedure: Consolidative Surgery
  • Study ID: NCT02365766
View Trial

A Randomised Phase II Trial of Adaptive Image Guided Standard or Dose Escalated Tumour Boost Radiotherapy in the Treatment of Transitional Cell Carcinoma of the Bladder

  • Condition: Bladder Cancer
  • Intervention: Radiation: WBRT, Radiation: SART, Radiation: DART
  • Study ID: NCT02447549
View Trial

A Phase II Study Investigating Preoperative MPDL3280A in Operable Transitional Cell Carcinoma of the Bladder (ABACUS)

  • Condition: Bladder Cancer
  • Intervention: Drug: MPDL3280A
  • Study ID: NCT02662309
View Trial

A Phase II Trial of MK3475 in Combination With Gemcitabine and Concurrent Hypofractionated Radiation Therapy as Bladder Sparing Treatment for Muscle-Invasive Urothelial Cancer of the Bladder

  • Condition: Muscle-invasive Urothelial Cancer of the Bladder
  • Intervention: Biological: Pembrolizumab, Procedure: Transurethral Resection of Bladder Tumor, Drug: Gemcitabine, Radiation: External Beam Radiation Therapy
  • Study ID: NCT02621151
View Trial

Phase I Study of Hypofractionated Radiotherapy and Anti-PD1 Antibody (Pembrolizumab) in the Treatment of Advanced Bladder Cancer

  • Condition: Invasive Bladder Cancer
  • Intervention: Drug: Pembrolizumab, Radiation: Radiotherapy
  • Study ID: NCT02560636
View Trial

A Phase II Study of Chemoradiation for Bladder Preservation in Patients With Muscle Invasive Bladder Carcinoma After Complete Response to Neoadjuvant Chemotherapy

  • Condition: Bladder Cancer, Bladder Carcinoma, Transition Cell Cancer, Muscle Invasive Bladder Carcinoma
  • Intervention: Procedure: Transurethral Resection of the Bladder Tumor & Cystoscopy, Radiation: Intensity Modulated Radiation Therapy, Behavioral: Expanded Prostate Cancer Index Composite Short Form 12, Behavioral: International Prostate Symptom Score
  • Study ID: NCT02145390
View Trial

MDSC Clinical Assay for Cancer Detection and Monitoring in Bladder Carcinoma

  • Condition: No Evidence of Disease, Stage II Bladder Cancer, Stage III Bladder Cancer, Stage IVA Bladder Cancer, Stage IVB Bladder Cancer
  • Intervention: Other: Cytology Specimen Collection Procedure, Other: Laboratory Biomarker Analysis
  • Study ID: NCT02735512
View Trial

Application-based Perioperative Management of the Radical Cystectomy Patient

  • Condition: Bladder Cancer
  • Intervention: Other: LifeScience Technologies application
  • Study ID: NCT02942121
View Trial

Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Observation After Curative Intent Resection of Cholangiocarcinoma and Muscle Invasive Gall Bladder Carcinoma (ACTICCA-1 Trial)

  • Condition: Cholangiocarcinoma, Gall Bladder Carcinoma
  • Intervention: Drug: Gemcitabine, Drug: Cisplatin, Other: Observation
  • Study ID: NCT02170090
View Trial

Prospective Randomized Trial of Adjuvant Radiotherapy Following Surgery and Chemotherapy in Muscle Invasive Transitional Cell Carcinoma of Urinary Bladder

  • Condition: Bladder Cancer, Urothelial Carcinoma Bladder
  • Intervention: Radiation: Adjuvant RT
  • Study ID: NCT02951325
View Trial

Open-Label, Multicenter, Ph 3 Study to Evaluate the Efficacy and Tolerability of Intravesical Vicinium™ in Subjects With Non Muscle-Invasive Carcinoma in Situ and/or High-Grade Papillary Disease of the Bladder Treated With BCG

  • Condition: Bladder Cancer
  • Intervention: Biological: Vicinium
  • Study ID: NCT02449239
View Trial

Phase II Study to Evaluate the Response to 2 Induction Courses (12 Intravesical Instillations) of Bacillus Calmette-Guérin (BCG) for High Risk Superficial Bladder Cancer

  • Condition: Bladder Cancer, High Risk Superficial
  • Intervention: Biological: Bacillus Calmette-Guérin (BCG)
  • Study ID: NCT02281383
View Trial

Randomised Controlled Multicenter Study.Effect of an Intensive Smoking- and/or Alcohol Cessation Intervention Placed Shortly Before and 5 Weeks After Bladder Cancer Surgery on Postoperative Complications

  • Condition: Bladder Cancer, Smoking, Alcohol Consumption
  • Intervention: Behavioral: Educational programme for smoking and alcohol cessation
  • Study ID: NCT02188446
View Trial

A Phase II Study of the Anti-PD-L1 Antibody MPDL3280A in Subjects With Non-metastatic Transitional Cell Carcinoma of the Bladder

  • Condition: Carcinoma, Transitional Cell
  • Intervention: Drug: MPDL3280A Dose Level 1, Drug: MPDL3280A Dose Level 2, Drug: MPDL3280A Dose Level 3
  • Study ID: NCT02451423
View Trial
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe